Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome

Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma

(2020) Qian Xing et al.   Annals of Translational Medicine

PD-1 inhibitor-associated severe myasthenia gravis with necrotizing myopathy and myocarditis

(2019) Hayato So et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

(2019) Filipe Martins et al.   Nature Reviews Clinical Oncology

Myocarditis in the Setting of Cancer Therapeutics

(2019) Marc P. Bonaca et al.   CIRCULATION

Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review

(2019) Thomopoulou Konstantina et al.   LUNG CANCER

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

(2018) Syed S. Mahmood et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

(2018) Javid J Moslehi et al.   LANCET

Immune Checkpoint Inhibitor–Associated Myositis

(2018) Céline Anquetil et al.   CIRCULATION

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

(2018) Daniel Y. Wang et al.   JAMA Oncology

Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti–programmed death 1 antibody

(2018) T. Shirai et al.   EUROPEAN JOURNAL OF CANCER

Immune Checkpoint Inhibitor Toxicity in 2018

(2018) Douglas B. Johnson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors

(2017) D. Makarious et al.   EUROPEAN JOURNAL OF CANCER

Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan

(2017) Shigeaki Suzuki et al.   NEUROLOGY

Myasthenic crisis and polymyositis induced by one dose of nivolumab

(2016) Toshihiro Kimura et al.   CANCER SCIENCE

Myasthenia gravis — autoantibody characteristics and their implications for therapy

(2016) Nils Erik Gilhus et al.   Nature Reviews Neurology

Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin

(2016) Elena Cortés-Vicente et al.   JAMA Neurology

Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma

(2015) Takushi Shirai et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY